Structure-Based Exploration and Exploitation of the S4 Subsite of Norovirus 3CL Protease in the Design of Potent and Permeable Inhibitors
Issue Date
2017-01-27Author
Kankanamalage, Anushka C. Galasiti
Rathnayake, Athri D.
Damalanka, Vishnu C.
Weerawarna, Pathum M.
Doyle, Sean T.
Alsoudi, Amer F.
Dissanayake, D. M. Padmasankha
Groutas, William C.
Kim, Yunjeong
Chang, Kyeong-Ok
Lushington, Gerald H.
Mehzabeen, Nurjahan
Lovell, Scott
Battaile, Kevin P.
Publisher
Elsevier
Type
Article
Article Version
Scholarly/refereed, author accepted manuscript
Rights
© 2017. This article is made available under an Attribution-NonCommercial-NoDerivs 3.0 Unported (CC BY-NC-ND 3.0) license.
Metadata
Show full item recordAbstract
Human noroviruses are the primary cause of epidemic and sporadic acute gastroenteritis. The worldwide high morbidity and mortality associated with norovirus infections, particularly among the elderly, immunocompromised patients and children, constitute a serious public health concern. There are currently no approved human vaccines or norovirus-specific small-molecule therapeutics or prophylactics. Norovirus 3CL protease has recently emerged as a potential therapeutic target for the development of anti-norovirus agents. We hypothesized that the S4 subsite of the enzyme may provide an effective means of designing potent and cell permeable inhibitors of the enzyme. We report herein the structure-guided exploration and exploitation of the S4 subsite of norovirus 3CL protease in the design and synthesis of effective inhibitors of the protease.
Collections
Citation
Galasiti Kankanamalage, A. C., Kim, Y., Rathnayake, A. D., Damalanka, V. C., Weerawarna, P. M., Doyle, S. T., … Groutas, W. C. (2017). Structure-Based Exploration and Exploitation of the S4 Subsite of Norovirus 3CL Protease in the Design of Potent and Permeable Inhibitors. European Journal of Medicinal Chemistry, 126, 502–516. http://doi.org/10.1016/j.ejmech.2016.11.027
Items in KU ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
We want to hear from you! Please share your stories about how Open Access to this item benefits YOU.